These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38203596)

  • 21. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.
    Kreuz S; Holmes KB; Tooze RM; Lefevre PF
    Mol Cancer; 2015 Dec; 14():205. PubMed ID: 26643319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases.
    Martín-Sánchez E; Odqvist L; Rodríguez-Pinilla SM; Sánchez-Beato M; Roncador G; Domínguez-González B; Blanco-Aparicio C; García Collazo AM; Cantalapiedra EG; Fernández JP; Curiel del Olmo S; Pisonero H; Madureira R; Almaraz C; Mollejo M; Alves FJ; Menárguez J; González-Palacios F; Rodríguez-Peralto JL; Ortiz-Romero PL; Real FX; García JF; Bischoff JR; Piris MA
    PLoS One; 2014; 9(11):e112148. PubMed ID: 25386922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CRISPR/Cas9-mediated knockout of PIM3 suppresses tumorigenesis and cancer cell stemness in human hepatoblastoma cells.
    Marayati R; Stafman LL; Williams AP; Bownes LV; Quinn CH; Markert HR; Easlick JL; Stewart JE; Crossman DK; Mroczek-Musulman E; Beierle EA
    Cancer Gene Ther; 2022 May; 29(5):558-572. PubMed ID: 33864024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The presence of PIM3 increases hepatoblastoma tumorigenesis and tumor initiating cell phenotype and is associated with decreased patient survival.
    Stafman LL; Waldrop MG; Williams AP; Aye JM; Stewart JE; Mroczek-Musulman E; Yoon KJ; Whelan K; Beierle EA
    J Pediatr Surg; 2019 Jun; 54(6):1206-1213. PubMed ID: 30898394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of PIM Kinases Promotes Neuroblastoma Cell Differentiation to a Neuronal Phenotype.
    Julson JR; Quinn CH; Bownes LV; Hutchins SC; Stewart JE; Aye J; Yoon KJ; Beierle EA
    J Pediatr Surg; 2023 Jun; 58(6):1155-1163. PubMed ID: 36907773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Organ-specific off-target effects of Pim/ZIP kinase inhibitors suggest lack of contractile Pim kinase activity in prostate, bladder, and vascular smooth muscle.
    Hu S; Trieb M; Huang R; Tamalunas A; Keller P; Götz M; Waidelich R; Stief CG; Hennenberg M
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Feb; 397(2):1219-1231. PubMed ID: 37658212
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma.
    Brunen D; de Vries RC; Lieftink C; Beijersbergen RL; Bernards R
    Mol Cancer Ther; 2018 Apr; 17(4):849-857. PubMed ID: 29440296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RNA-Seq analysis reveals that spring viraemia of carp virus induces a broad spectrum of PIM kinases in zebrafish kidney that promote viral entry.
    Pereiro P; Álvarez-Rodríguez M; Valenzuela-Muñoz V; Gallardo-Escárate C; Figueras A; Novoa B
    Fish Shellfish Immunol; 2020 Apr; 99():86-98. PubMed ID: 32004617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin receptor substrate 1 is a substrate of the Pim protein kinases.
    Song JH; Padi SK; Luevano LA; Minden MD; DeAngelo DJ; Hardiman G; Ball LE; Warfel NA; Kraft AS
    Oncotarget; 2016 Apr; 7(15):20152-65. PubMed ID: 26956053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PIM-1 kinase is a novel regulator of proinflammatory cytokine-mediated responses in rheumatoid arthritis fibroblast-like synoviocytes.
    Ha YJ; Choi YS; Han DW; Kang EH; Yoo IS; Kim JH; Kang SW; Lee EY; Song YW; Lee YJ
    Rheumatology (Oxford); 2019 Jan; 58(1):154-164. PubMed ID: 30204915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
    Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
    PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of phosphatidylinositol-3'-kinase/AKT signaling is essential in hepatoblastoma survival.
    Hartmann W; Küchler J; Koch A; Friedrichs N; Waha A; Endl E; Czerwitzki J; Metzger D; Steiner S; Wurst P; Leuschner I; von Schweinitz D; Buettner R; Pietsch T
    Clin Cancer Res; 2009 Jul; 15(14):4538-45. PubMed ID: 19584164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling.
    Cen B; Xiong Y; Song JH; Mahajan S; DuPont R; McEachern K; DeAngelo DJ; Cortes JE; Minden MD; Ebens A; Mims A; LaRue AC; Kraft AS
    Mol Cell Biol; 2014 Jul; 34(13):2517-32. PubMed ID: 24777602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell-Specific Computational Modeling of the PIM Pathway in Acute Myeloid Leukemia.
    Silverbush D; Grosskurth S; Wang D; Powell F; Gottgens B; Dry J; Fisher J
    Cancer Res; 2017 Feb; 77(4):827-838. PubMed ID: 27965317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.
    Yu Y; Zhao X; Zhang Y; Kang Y; Wang J; Liu Y
    Oncol Rep; 2015 Jul; 34(1):407-14. PubMed ID: 25955434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.
    Warfel NA; Sainz AG; Song JH; Kraft AS
    Mol Cancer Ther; 2016 Jul; 15(7):1637-47. PubMed ID: 27196781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes.
    Mumenthaler SM; Ng PY; Hodge A; Bearss D; Berk G; Kanekal S; Redkar S; Taverna P; Agus DB; Jain A
    Mol Cancer Ther; 2009 Oct; 8(10):2882-93. PubMed ID: 19825806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-tumour effects of PIM kinase inhibition on progression and chemoresistance of hepatocellular carcinoma.
    Leung MS; Chan KK; Dai WJ; Wong CY; Au KY; Wong PY; Wong CC; Lee TK; Ng IO; Kao WJ; Lo RC
    J Pathol; 2020 Sep; 252(1):65-76. PubMed ID: 32558942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer.
    Luszczak S; Simpson BS; Stopka-Farooqui U; Sathyadevan VK; Echeverria LMC; Kumar C; Costa H; Haider A; Freeman A; Jameson C; Ratynska M; Ben-Salha I; Sridhar A; Shaw G; Kelly JD; Pye H; Gately KA; Whitaker HC; Heavey S
    Sci Rep; 2020 Sep; 10(1):14380. PubMed ID: 32873828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts.
    Eicher C; Dewerth A; Thomale J; Ellerkamp V; Hildenbrand S; Warmann SW; Fuchs J; Armeanu-Ebinger S
    Br J Cancer; 2013 Feb; 108(2):334-41. PubMed ID: 23257893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.